Multimodality Intravascular Imaging to Predict Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention  by Kini, Annapoorna S. et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S VO L . 8 , N O . 7 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 5 . 0 3 . 0 1 6Multimodality Intravascular Imaging
to Predict Periprocedural Myocardial
Infarction During Percutaneous
Coronary Intervention
Annapoorna S. Kini, MD, Sadako Motoyama, MD, PHD, Yuliya Vengrenyuk, PHD, Jonathan E. Feig, MD, PHD,
Jacobo Pena, MD, Usman Baber, MD, Arjun M. Bhat, MD, Pedro Moreno, MD, Jason C. Kovacic, MD, PHD,
Jagat Narula, MD, PHD, Samin K. Sharma, MDABSTRACTFro
Mo
an
rec
Sci
rel
MaOBJECTIVES The aim of this study is to compare the relative merits of optical coherence tomography (OCT), intra-
vascular ultrasound (IVUS), and near infrared spectroscopy (NIRS) in patients with coronary artery disease for the pre-
diction of periprocedural myocardial infarction (MI).
BACKGROUND Although several individual intravascular imaging modalities have been employed to predict peripro-
cedural MI, it is unclear which of the imaging tools would best allow prediction of this complication.
METHODS We retrospectively analyzed 110 patients who underwent OCT, IVUS, and NIRS. Periprocedural MI was
deﬁned as a post-procedural cardiac troponin I (cTnI) elevation above 3 the upper limit of normal; analysis was also
performed for cTnI $5 the upper limit of normal.
RESULTS cTnI$3 was observed in 10 patients (9%) and 8 patients had cTnI$5. By OCT, minimum cap thickness was
signiﬁcantly lower (55 vs. 90 mm, p < 0.01), and the plaque burden by IVUS (84  9% vs. 77  8%, p < 0.01) and
maximum 4-mm lipid core burden index by NIRS (556 vs. 339, p < 0.01) were greater in the cTnI$3 group. Multivariate
logistic regression analysis identiﬁed cap thickness as the only independent predictor for cTnI $3 the upper limit of
normal (odds ratio [OR]: 0.90, p ¼ 0.02) or cTnI $5 (OR: 0.91, p ¼ 0.04). If OCT ﬁndings were excluded from the
analysis, plaque burden (OR: 1.13, p ¼ 0.045) and maximum 4-mm lipid core burden index (OR: 1.003, p ¼ 0.037)
emerged to be the independent predictors.
CONCLUSIONS OCT-based ﬁbrous cap thickness is the most important predictor of periprocedural MI. In the absence
of information about cap thickness, NIRS lipid core or IVUS plaque burden best determined the likelihood of the peri-
procedural event. (J Am Coll Cardiol Intv 2015;8:937–45) © 2015 by the American College of Cardiology Foundation.M yocardial damage after percutaneouscoronary intervention (PCI) deﬁned ascardiac troponin elevation has been re-
ported as a procedural complication in about 10% to
50% of patients (1–4). Post-PCI cardiac troponin
elevation has been reported to be associated with
increased adverse short- and intermediate-termm the Division of Cardiology, Mount Sinai Hospital and Icahn School of
reno is a founder and stockholder of Infraredx, Inc., the company that pr
d has received speaker fees from AstraZeneca. Dr. Kovacic has received
eived research grants from Philips and GE Healthcare. Dr. Sharma has rec
entiﬁc, Cardiovascular Systems Inc., and Daiichi Sankyo/Lilly. All other au
evant to the contents of this paper to disclose.
nuscript received December 17, 2014; revised manuscript received Februoutcomes (5–10). This complication has been
frequently attributed to large, lipid-rich plaques
that could embolize and release necrotic debris
into the distal circulation. Several intravascular imag-
ing modalities such as optical coherence tomog-
raphy (OCT) (11–14), intravascular ultrasound (IVUS)
(3,14–16), IVUS–virtual histology (16), near infraredMedicine at Mount Sinai, New York, New York. Dr.
oduces the near-infrared catheter used in this study;
research support form AstraZeneca. Dr. Narula has
eived speaking fees from Abbott, Angioscore, Boston
thors have reported that they have no relationships
ary 24, 2015, accepted March 21, 2015.
ABBR EV I A T I ON S
AND ACRONYMS
CI = conﬁdence interval
CSA = cross-sectional area
cTnI = cardiac troponin I
IVUS = intravascular
ultrasound
LCBI = lipid core burden index
maxLCBI4mm = maximum
4-mm lipid core burden index
MI = myocardial infarction
MLA = minimal lumen area
NIRS = near infrared
spectroscopy
OCT = optical coherence
tomography
OR = odds ratio
PCI = percutaneous coronary
intervention
TCFA = thin cap ﬁbroatheroma
TIMI = Thrombolysis in
Myocardial Infarction
ULN = upper limit of normal
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938spectroscopy (NIRS) (17,18), and noninvasive
computed tomography angiography imaging
(19,20) have been employed to predict peri-
procedural myocardial infarction (MI). Lesion
characteristics, associated with this peripro-
cedural complication, include a thin ﬁbrous
cap with wide lipid attenuation arc veriﬁed
by OCT, large attenuated plaque area with
positive remodeling detected by grayscale
IVUS, large IVUS–virtual histology necrotic
core, and virtual histology thin cap ﬁbroa-
theroma (TCFA) (21), TCFA on radiofre-
quency IVUS, or high lipid core burden
demonstrated by NIRS. All of these modal-
ities have demonstrated variable effective-
ness in predicting complications based on
the strength of the employed imaging strat-
egy. Although OCT, IVUS, and NIRS are all
able to recognize lipid-rich plaques, it is still
unclear which of these available imaging
tools would allow for the most accurate pre-
diction of periprocedural MI. Accordingly,
we sought to simultaneously compare the
IVUS, OCT, and NIRS imaging-based metricsfor the risk of periprocedural MI in patients with sta-
ble ischemic heart disease.SEE PAGE 946METHODS
Study populat ion . This study was a retrospective
analysis of prospectively collected data from the
institutional review board–approved clinical and
multimodality imaging database. All procedures were
done in the Mount Sinai Cardiac Catheterization Lab.
The baseline demographic, clinical, procedural, and
in-hospital outcomes data and imaging characteris-
tics were obtained from the database. The study
group comprised 133 consecutive patients referred for
cardiac catheterization for evaluation of coronary
artery disease who had undergone OCT and IVUS/
NIRS imaging. All cases represented de novo athero-
sclerosis. Of these 133 patients, 23 were excluded
because 18 patients had baseline cardiac troponin I
(cTnI) levels above the upper limit of normal (ULN)
and in 5 patients image quality was not deemed to be
optimum. The remaining 110 patients were analyzed.
One hundred and ten patients included in the
study also formed a part of COLOR (Chemometric
Observation of Lipid Core Plaques of Interest in
Native Coronary Arteries) registry enrolled only from
our center. Patients with renal failure (creatinine
>1.5 mg/dl), hemodynamic compromise, contrastallergy, and aorto-ostial coronary artery lesions were
excluded from the study. The lesion to scan and treat
was selected on operator’s discretion after the diag-
nostic angiogram. NIRS/IVUS and OCT were per-
formed on identical segments of the same coronary
artery before PCI. Patients with baseline cTnI levels
above ULN were not included in this study. Peri-
procedural MI was deﬁned as cTnI elevation above
3 ULN measured 6 to 24 h after PCI; patients were
divided into 2 groups of cTnI elevation: $3 and <3.
Analysis was also performed for the evaluation
above 5 ULN in accordance with the third universal
deﬁnition of MI (22). ULN was deﬁned as 0.5 ng/ml.
Coronary angiographic data and PCI. PCI was performed
according to standard methods, and images were
stored digitally. About 80% of patients received P2Y12
inhibitor loading on the table with maintenance dose
for 1 year. All patients received standard bivalirudin
bolus and infusion. The target lesion undergoing PCI
was identiﬁed and quantitative analyses were per-
formed to determine the percentage of diameter ste-
nosis. The lesion to scan and treat was selected based
on the operator’s discretion after the diagnostic
angiogram (1 target lesion per patient). After bivalir-
udin administration (activated clotting time >300 s),
imaging (OCT and combined NIRS-IVUS) was per-
formed. Angiography review was done by a cardiol-
ogist (U.B.) who was blinded to patient characteristics
and other imaging ﬁndings. OCT, IVUS, and NIRS
images were analyzed off-line by 3 experienced ana-
lysts (Y.V., J.P., S.M.).
OCT image acqu is i t ion and analys i s . OCT image
acquisition was performed with a commercially
available C7-XR OCT Intravascular Imaging System
(OCT C7 Dragonﬂy, St. Jude Medical, St. Paul, Min-
nesota). The OCT catheter was placed at least 10 mm
distally to the imaging target lesion. OCT image
acquisition was then performed with continuous
intracoronary contrast injection (iodixanol) (total
volume 12 to 16 ml injected at 3 to 4 ml/s) and
simultaneous OCT catheter pullback at 20 mm/s. Each
OCT catheter pullback imaged a total of 54 mm of the
vessel.
OCT images were analyzed systematically at 1-mm
intervals according to previously validated criteria for
plaque characterization (23,24) using the St. Jude
Medical Ofﬂine Review Workstation as we described
previously (25,26). The smallest cross-sectional area
(CSA), reference CSA, and percentage of lumen area
stenosis were calculated for each lesion. For each
lipid plaque, the lipid arc was measured at 1-mm
intervals through the entire length of the lesion
expressed in degrees. Lipid length was measured
on longitudinal view (using frame analysis). Lipid
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939volume index was calculated as the averaged lipid arc
multiplied by lipid length (27). Fibrous cap thickness
was estimated by measuring the thinnest signal-rich
zone separating the lipid content from the vessel
lumen in the entire stenosis (in mm). The thinnest part
of the ﬁbrous cap was measured 3 and its average
was deﬁned as minimum cap thickness. OCT-TCFA
was deﬁned as a plaque with lipid arc >90 and
ﬁbrous cap thickness <65 mm. Areas with well-
deﬁned borders were classiﬁed as calciﬁed plaques
with the degree of circumferential extent of calciﬁ-
cation quantiﬁed at 1-mm intervals. Spotty calciﬁca-
tion was deﬁned as a calciﬁed plaque <4 mm in
length with calciﬁcation arc <90

(11). A microchannel
was deﬁned as a black hole or tubular structure
within a plaque not connected to the vessel lumen
and present on at least 3 consecutive cross-sectional
OCT images (28). To evaluate the interobserver vari-
ability, 3 experienced OCT analysts reviewed OCT
pullbacks independently, and the analyses were
repeated at intervals of at least 2 weeks by the ﬁrst
observer.
Combined graysca le IVUS and NIRS image
acqui s i t ion and analys i s . Grayscale IVUS and NIRS
image acquisition was performed using the commer-
cially available TVC Imaging System with the TVC
Insight catheter (Infraredx, Burlington, Massachu-
setts). Quantitative grayscale IVUS analysis was
performed using QIvus 3.0 (MEDIS, Leiden, the
Netherlands) to estimate lumen and reference CSA,
external elastic membrane CSA, plaque plus media
CSA, plaque burden, and remodeling index as
described previously (25,26) according to the Amer-
ican College of Cardiology consensus statement (29).
Qualitative analysis included ultrasonic attenuation
behind the plaque in the absence of calciﬁcation (30).
The raw spectra of NIRS estimate the probability of
the presence of an atherosclerotic lipid core. The
measurements are displayed as a chemogram, which
represents a spectroscopic image of the scanned
lesion and allows to calculate lipid core burden index
(LCBI) (31,32). In the present study, the maximal LCBI
was estimated in 4-mm pullback compartments
by identifying the maximum LCBI subsegment for
every analyzed lesion (maxLCBI4mm) as previously
described (17).
Image coreg ist rat ion . OCT and combined NIRS-
IVUS pullbacks were coregistered using anatomical
landmarks (ﬁduciary points). Vascular and peri-
vascular markings were used to conﬁrm simultaneous
assessment of IVUS measurements and OCT analysis
in the same lesion.
Stat i s t i ca l analys i s . Interobserver agreement and
intraobserver reproducibility of imaging parametermeasurements were assessed by intraclass correla-
tion coefﬁcients based on the random effects analysis
of variance models (33). The Shapiro-Wilk test was
used to assess the normality of continuous data. All
continuous measurements were expressed as mean 
SD for normally distributed variables or median and
interquartile range (25th percentile, 75th percentile)
for nonparametric data and compared using Pearson
correlation and Wilcoxon signed-rank test, respec-
tively. Categorical variables are presented as fre-
quencies (percentages) and were compared using the
chi-square test or Fisher exact test. To identify the
independent correlates of periprocedural MI, we
ﬁtted a multivariable logistic regression model with
periprocedural MI as the dependent outcome. Vari-
ables demonstrating a signiﬁcant univariable associ-
ation with this outcome of interest were included as
candidate covariates in this model. Given the limited
number of outcomes in our study, we performed a
sensitivity analysis using both backward and forward
stepwise selection to assess model consistency. These
analyses yielded similar results to the fully ﬁtted
model. The multivariable analyses were performed
both for 3 and 5 elevation in cTnI levels for
deﬁning MI. Results are reported as unit odds ratios
(ORs) with 95% conﬁdence intervals (CIs) and chi-
squared. Because OCT imaging emerged as the lead-
ing modality for prediction of periprocedural cTnI
elevation, another set of analyses was performed by
excluding OCT information to critically evaluate the
importance of other imaging modalities. All statistical
analysis was performed using SPSS statistical soft-
ware (version 22.0, SPSS Inc., Chicago, Illinois) with a
2-tailed probability value <0.05 considered statisti-
cally signiﬁcant.
RESULTS
Patient characteristics—angiographic and procedural
results. The baseline clinical demographics for 110
patients including coronary risk factors and lipid
proﬁles are summarized in Table 1. The mean age of
the patients was 63.4  11.9 years, and 83 (75%) were
male. cTnI $3 ULN was observed in 10 patients (9%);
all cTnI $3 ULN were male patients (100% vs. 73%,
p ¼ 0.06). There were no signiﬁcant differences in the
baseline clinical characteristics between the patients
who did or did not develop periprocedural MI. Ca-
nadian Cardiovascular Society angina grade III to IV
was observed in 63 patients (57%), but there was no
difference in severity of angina between the groups
(60% vs. 57%, p ¼ 0.85) with and without the troponin
leak. Importantly, the number of patients on statins
was not different (90% vs. 70%, p ¼ 0.18). The lipid
TABLE 1 Baseline Clinical Demographics
cTnI Elevation $3
(n ¼ 10)
cTnI Elevation <3
(n ¼ 100) p Value
Age, yrs 59.5  14.0 63.7  11.7 0.29
Male 10 (100) 73 (73) 0.06
Hypertension 8 (80) 91 (91) 0.27
Dyslipidemia 9 (90) 86 (86) 0.73
Diabetes mellitus 5 (50) 40 (40) 0.58
Current smoking 5 (50) 34 (34) 0.31
BMI, kg/m2 28.3  4.3 29.4  5.9 0.59
Previous MI 0 11 (11) 0.27
CCS angina grade III or IV 6 (60) 57 (57) 0.85
Statin use 9 (90) 70 (70) 0.18
Antiplatelet therapy 0.26
Clopidogrel 7 (70) 85 (85)
Prasugrel 2 (20) 6 (6)
Ticagrelor 1 (10) 9 (9)
GP IIb/IIIa inhibitors 2 (20) 16 (16) 0.74
Total cholesterol, mg/dl 137 (123–155) 141 (119–178) 0.48
HDL cholesterol, mg/dl 38 (32–49) 39 (31–47) 0.87
LDL cholesterol, mg/dl 74 (52–97) 77 (58–110) 0.30
Triglyceride, mg/dl 139 (64–142) 101 (70–146) 0.59
Values are mean  SD, n (%), or median (interquartile range).
BMI ¼ body mass index; CCS ¼ Canadian Cardiovascular Society; cTnI ¼ cardiac troponin I;
GP ¼ glycoprotein; HDL ¼ high-density lipoprotein cholesterol; LDL ¼ low-density lipoprotein
cholesterol; MI ¼ myocardial infarction.
TABLE 2 Angiograph
Target lesion: RCA/LAD
SYNTAX score
Degree of stenosis, %
Number of treated lesi
Number of treated lesi
Number of stents: 1/2/
Number of stents
Stent length, mm
Number of pre-dilation
Number of post-dilatio
Max balloon pressure,
Transient no reﬂow du
Values are n, median (inter
LAD ¼ left anterior desce
RCA ¼ right coronary arter
Cardiac Surgery; other abb
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940proﬁle did not reveal signiﬁcant differences in total
cholesterol (137 vs. 141 mg/dl, p ¼ 0.48), high-density
lipoprotein cholesterol (38 vs. 39 mg/dl, p ¼ 0.87),
low-density lipoprotein cholesterol (74 vs. 77 mg/dl,
p ¼ 0.30), or triglyceride (139 vs. 101 mg/dl, p ¼ 0.59)
levels between the cTnI $3 and cTnI <3 groups. All
patients were treated with antiplatelet therapy; the
frequency of each drug was similar in all groups. Inic and Procedural Findings
cTnI Elevation $3 cTnI Elevation <3 p Value
/LCX 4/4/2 (40/40/20) 31/53/16 (31/53/16) 0.76
8 (3–18) 8 (5–13) 0.91
85.5  9.0 83.9  10.0 0.62
ons: 1/2 10/0 (100/0) 94/6 (94/6) 0.43
ons 1 (1–1) 1 (1–1) 0.44
3 9/1/0 (90/10/0) 79/19/2 (79/19/2) 0.69
1 (1–1) 1 (1–1) 0.41
25 (21–29) 30 (23–38) 0.21
s 9 (90) 68 (68) 0.15
ns 7 (70) 78 (78) 0.54
atm 16 (12–16) 16 (14–18) 0.79
ring PCI 3 (30) 0 <0.01
quartile range), mean  SD, or n (%).
nding artery; LCX ¼ left circumﬂex artery; PCI ¼ percutaneous coronary intervention;
y; SYNTAX ¼ Synergy Between Percutaneous Coronary Intervention With Taxus and
reviations as in Table 1.addition, there was no difference in glycoprotein IIb/
IIIa Inhibitors use. Of the 10 patients with cTnI $3
elevation, 8 patients had $5 elevation per recom-
mendation of the third universal deﬁnition of MI.
Angiographic ﬁndings are summarized in Table 2. All
lesions were treated with drug-eluting stents. There
were no signiﬁcant differences in the distribution of
target lesions, SYNTAX (Synergy Between Percuta-
neous Coronary Intervention With Taxus and Cardiac
Surgery) score, number of treated lesions and
implanted stents, stent length, number of pre- and
post-dilations, or the maximum balloon pressure.
Transient no-reﬂow was observed in 3 patients from
the cTnI $3 group (30% vs. 0%, p < 0.01), but post-
PCI TIMI (Thrombolysis in Myocardial Infarction) ﬂow
grade 3 was achieved in all patients at the end of the
procedure and no side branch occlusion was
documented.
OCT ﬁndings . Pre-PCI OCT ﬁndings are shown in
Table 3. Although reference lumen CSA was not
signiﬁcantly different between the cTnI $3 and
cTnI <3 groups, minimum lumen CSA (1.2 vs.
1.9 mm2, p ¼ 0.02) and lumen area stenosis (80  8%
vs. 69  13%, p ¼ 0.03) indicated signiﬁcantly severe
lesions in the cTnI $3 group. Maximum lipid arc,
lipid length, and lipid volume index were greater in
the cTnI $3 group. Of 10 cTnI $3 patients,
8 (80%) demonstrated $180 OCT lipid arc. Minimum
cap thickness was signiﬁcantly lower in the cTnI $3
group (55 vs. 90 mm, p < 0.001). Thin ﬁbrous cap
(<65 mm) was observed in 29 patients (26%); 9 of
29 (31%) had cTnI $3 elevation. Thin ﬁbrous cap
was signiﬁcantly more frequent in the cTnI $3
group than in the cTnI <3 group (90% vs. 20%,
p < 0.01). TCFA (cap thickness <65 mm and lipid arc
>90) was observed in 27 patients (25%) and was also
signiﬁcantly more frequent in the cTnI $3 group
(80% vs. 19%, p < 0.01) (Table 3, Figure 1). The
thinnest cap was observed proximal to the minimal
lumen area (MLA) in 56% and distal to MLA in 19% of
TCFA. In 26% of the lesions, the location of the
thinnest cap coincided with the minimum lumen
site. One TCFA lesion was observed per stenosis. The
features of plaque rupture, thrombus, microvessels,
and the incidence of spotty calciﬁcation were not
signiﬁcantly different between the 2 groups. Intra-
class correlation coefﬁcient for interobserver and
intraobserver variability for the maximum lipid arc
was 0.98 (95% CI: 0.932 to 0.997) and 0.99 (95% CI:
0.965 to 0.998), respectively; for ﬁbrous cap thick-
ness was 0.96 (95% CI: 0.875 to 0.991) and 0.98 (95%
CI: 0.933 to 0.997), respectively.
IVUS and NIRS imaging ﬁndings . Grayscale IVUS
quantitative measurements at the reference location
TABLE 3 OCT, IVUS, and NIRS Findings
cTnI Elevation $3 cTnI Elevation <3 p Value
OCT
Reference lumen CSA, mm2 6.5 (4.0–8.1) 6.4 (4.8–8.1) 0.83
Minimum lumen CSA, mm2 1.2 (1.1–1.3) 1.9 (1.2–2.7) 0.02
Area stenosis, % 79.4  7.8 68.8  13.3 0.03
Lipid arc maximum,  237 (181–259) 176 (103–265) 0.19
Lipid arc, number of quadrants 0.06
1 1 (10) 21 (21)
2 1 (10) 30 (30)
3 7 (70) 28 (28)
4 1 (10) 21 (21)
Lipid length, mm 8 (5–11) 5 (2–10) 0.14
Lipid volume index 1,375 (594–2,831) 632 (201–1,431) 0.06
Minimum cap thickness, mm 55 (50–60) 90 (70–120) <0.01
Minimum cap thickness <65 mm 9 (90) 20 (20) <0.01
TCFA 8 (80) 19 (19) <0.01
Plaque rupture 2 (20) 8 (8) 0.21
Thrombus 1 (10) 3 (3) 0.26
Microvessel 4 (40) 46 (46) 0.72
Calcium deposition 10 (100) 78 (78) 0.10
Spotty calciﬁcation 7 (70) 41 (41) 0.08
Calcium arc maximum,  104 (74–265) 107 (75–167) 0.69
IVUS
Reference
EEM CSA, mm2 14.6 (9.4–19.1) 13.5 (11.0–16.2) 1.00
Lumen CSA, mm2 8.8 (4.9–11.6) 7.2 (6.0–9.3) 0.70
P&M CSA, mm2 5.1 (2.8–10.1) 5.8 (4.1–7.3) 0.62
Plaque burden, % 40.8  14.0 42.7  12.5 0.66
Minimum lumen site
EEM CSA, mm2 14.7 (9.7–21.1) 13.1 (10.5–16.0) 0.39
Lumen CSA, mm2 2.3  0.6 3.0  0.8 0.02
P&M CSA, mm2 13.4 (7.6–21.4) 10.6 (8.7–13.8) 0.31
Plaque burden, % 83.8  9.0 77.1  7.6 <0.01
Remodeling index 1.10 (0.97–1.19) 0.96 (0.84–1.10) 0.06
Attenuation 9 (90) 61 (61) 0.02
NIRS
maxLCBI4mm 556 (479–650) 339 (199–512) <0.01
maxLCBI4mm $500 8 (80) 25 (25) <0.01
Values are median (interquartile range), mean  SD, or n (%).
CSA ¼ cross-sectional area; cTnI ¼ cardiac troponin I; EEM ¼ external elastic membrane; IVUS ¼ intravascular
ultrasound; maxLCBI4mm ¼ maximum 4-mm lipid core burden index; NIRS ¼ near infrared spectroscopy; OCT ¼
optical coherence tomography; P&M ¼ plaque plus media; TCFA ¼ thin cap ﬁbroatheroma.
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941were similar in both groups (Table 3). Minimum
lumen CSA was signiﬁcantly smaller (2.3  0.6 mm2
vs. 3.0  0.8 mm2, p ¼ 0.02) and the plaque burden
was signiﬁcantly larger (83.8  9.0% vs. 77.1  7.6%,
p < 0.01) in the cTnI $3 group. Remodeling index
tended to be larger in the cTnI $3 group (1.10 vs.
0.96, p ¼ 0.06). Our grayscale morphological analysis
showed that attenuated plaques were more
frequently found in the cTnI $3 group (90% vs. 61%,
p ¼ 0.02). MaxLCBI4mm was signiﬁcantly larger in
patients with cTnI $3 than in those with cTnI <3
(556 vs. 339, p < 0.01). MaxLCBI4mm $500 was
observed in 33 patients (30%); 8 of 33 (24%) had
cTnI $3 elevation. MaxLCBI4mm $500 was more
frequent in the cTnI $3 group (80% vs. 25%,
p < 0.01). There was an overlap between MLA and
maxLCBI4mm segment in the majority of analyzed
lesions (85%) in NIRS/IVUS pullback: the maximum
lipid segment was proximal to MLA in 11% and distal
to MLA in 4% of the lesions.
Predictors of per iprocedura l MI . With univariate
logistic regression analysis, the cap thickness (OR:
0.89, chi-squared: 7.48, p < 0.01) by OCT, plaque
burden (OR: 1.16, chi-squared: 6.14, p ¼ 0.01) by IVUS,
and maxLCBI4mm (OR: 1.004, chi-squared: 7.18, p <
0.01) by NIRS were important predictors of peri-
procedural MI (Table 4). Multivariate logistic regres-
sion analysis revealed OCT-veriﬁed cap thickness to
be the only independent predictor for cTnI$3 ULN
(OR: 0.90, chi-squared: 5.55, p ¼ 0.02); the cap
thickness was also the sole predictor of cTnI $5 (OR:
0.91, chi-squared: 4.36, p ¼ 0.04). If all OCT ﬁndings
were excluded from the analysis, plaque burden by
IVUS (OR: 1.13, chi-squared: 4.04, p ¼ 0.045) and
maxLCBI4mm by NIRS (OR: 1.003, chi-squared: 4.33,
p ¼ 0.037) emerged to be the independent predictors.
MaxLCBI4mm OR on a per-100-unit LCBI scale is pre-
sented in Online Table 1.
DISCUSSION
Although PCI achieves excellent angiographic suc-
cess, approximately 3% to 15% of cases are compli-
cated by periprocedural MI, which is associated with
adverse long-term outcomes (1,2). Whereas numerous
studies have previously evaluated the importance of
individual imaging ﬁndings by OCT, IVUS, or NIRS
for the evaluation of periprocedural MI (11,12,14,16),
we have done the following: 1) performed head-
to-head comparison of the all 3 imaging modalities;
2) demonstrated that OCT-veriﬁed TCFA was the only
independent predictor for periprocedural MI; and
3) showed that in the absence of information about
ﬁbrous cap thickness (or OCT ﬁndings), plaqueburden by IVUS or lipid core by NIRS best determined
the likelihood of the periprocedural event.
IVUS is a useful tool to measure the lumen and
plaque size. However, the spatial resolution of IVUS
(approximately 100 to 250 mm) does not allow
assessment of cap thickness, and it is difﬁcult to
demonstrate lipid area or lipid volume quantitatively.
In addition to grayscale IVUS, radiofrequency IVUS or
integrated backscatter IVUS facilitate analysis of the
plaque composition. Several IVUS studies including a
meta-analysis have reported the association of large
plaque burden and the extent of necrotic core with
FIGURE 1 Multimodality Imaging of a Representative Case With Periprocedural MI
(A) Coronary angiography demonstrating signiﬁcant stenosis in the left anterior descending coronary artery. (B) Near infrared spectroscopy
chemogram. Yellow indicates a high probability of lipid-rich plaque. Maximum 4-mm lipid core burden index (maxLCBI4mm) was 482. (C)
Optical coherence tomography image of thin cap ﬁbroatheroma lesion. Lipid arc is 159 (dashed semicircular arrow) and ﬁbrous cap thickness
at the thinnest portion is 60 mm (solid arrow). (D) Intravascular ultrasound shows plaque burden at the site of minimum lumen equal to 78%.
The location of optical coherence tomography/intravascular ultrasound frames (C,D) and maxLCBI4mm segment (B) is shown by arrows and
white line in angiogram (A).
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942cardiac troponin elevation after PCI (3,15,27).
Although this imaging modality has greatly enhanced
our understanding of plaque dynamics, it has major
limitations. Over the last few years, other imaging
techniques with great promise have been employed
to provide more insight into plaque composition.
NIRS provides an assessment of the lipid content of
plaques by identifying the presence of cholesterol
monohydrate and cholesterol ester. Several studies
have shown that it can accurately identify lipid-richregions (26,31,32). We recently demonstrated in the
randomized prospective YELLOW (Reduction in Yel-
low Plaque by Aggressive Lipid Lowering Therapy)
trial (34) that short-term intensive statin therapy may
reduce lipid content in obstructive lesion as assessed
by NIRS. Goldstein et al. (17) described the relation-
ship between the presence of a large lipid core plaque
as detected by NIRS and periprocedural MI. Stable
patients undergoing PCI were identiﬁed from the
COLOR registry, a prospective observational study of
T
A
B
L
E
4
U
ni
va
ri
at
e
an
d
M
ul
ti
va
ri
at
e
Lo
g
is
ti
c
R
eg
re
ss
io
n
A
na
ly
si
s
fo
r
P
re
di
ct
in
g
P
er
ip
ro
ce
du
ra
l
M
I
by
O
CT
,
IV
U
S,
an
d
N
IR
S
In
cl
ud
e
A
ll
Im
ag
in
g
M
od
al
it
ie
s
Ex
cl
ud
e
O
CT
cT
nI
El
ev
at
io
n
$
3
(n
¼
10
;9
%
)
cT
nI
El
ev
at
io
n
$
5
(n
¼
8
;7
%
)
cT
nI
El
ev
at
io
n
$
3
(n
¼
10
;9
%
)
U
ni
va
ri
at
e
M
ul
ti
va
ri
at
e
M
ul
ti
va
ri
at
e
M
ul
ti
va
ri
at
e
U
ni
t
O
R
(9
5%
CI
)
Ch
i-
Sq
ua
re
d
p
V
al
ue
U
ni
t
O
R
(9
5%
CI
)
Ch
i-
Sq
ua
re
d
p
V
al
ue
U
ni
t
O
R
(9
5%
CI
)
Ch
i-
Sq
ua
re
d
p
V
al
ue
U
n
it
O
R
(9
5%
CI
)
Ch
i-
Sq
ua
re
d
p
V
al
ue
O
CT L
ip
id
ar
c,

1.
0
0
4
(0
.9
9
8
–
1.
0
12
)
1.
8
3
0
.1
7
Li
pi
d
le
ng
th
,
m
m
1.
0
6
1
(0
.9
49
–
1.
17
4)
1.
27
0
.2
5
Ca
p
th
ic
kn
es
s,
mm
0
.8
8
6
(0
.7
9
6
–
0
.8
49
)
7.
48
<
0
.0
1
0
.8
9
6
(0
.7
9
9
–
0
.9
6
2)
5.
55
0
.0
2
0
.9
0
7
(0
.8
0
9
–
0
.9
75
)
4.
36
0
.0
4
IV
U
S Pl
aq
ue
bu
rd
en
,
%
1.
16
1
(1
.0
43
–
1.
32
6
)
6
.1
4
0
.0
1
1.
0
40
(0
.9
27
–
1.
19
5)
0
.3
8
0
.5
4
1.
11
8
(0
.9
72
–
1.
33
8
)
1.
9
2
0
.1
7
1.
13
4
(1
.0
14
–
1.
30
0
)
4.
0
4
0
.0
45
R
em
od
el
in
g
in
de
x,
%
1.
0
28
(0
.9
9
5–
1.
0
6
4)
2.
70
0
.1
0
N
IR
S m
ax
LC
B
I 4
m
m
1.
0
0
4
(1
.0
0
1–
1.
0
0
7)
7.
18
<
0
.0
1
1.
0
0
1
(0
.9
9
7–
1.
0
0
5)
0
.2
1
0
.6
5
1.
0
0
0
(0
.9
9
5–
1.
0
0
4)
0
.0
3
0
.8
7
1.
0
0
3
(1
.0
0
0
–
1.
0
0
6
)
4.
33
0
.0
37
CI
¼
co
nﬁ
de
nc
e
in
te
rv
al
;
O
R
¼
od
ds
ra
ti
o;
ot
he
r
ab
br
ev
ia
ti
on
s
as
in
Ta
bl
es
1
an
d
3.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 7 , 2 0 1 5 Kini et al.
J U N E 2 0 1 5 : 9 3 7 – 4 5 Multimodality Imaging for Periprocedural MI
943patients undergoing NIRS prior to PCI, whereas a
large lipid core plaque (maxLCBI4mm >500) was
identiﬁed in 22.6% of patients, and periprocedural MI
only occurred in 9 cases. Importantly, periprocedural
MI occurred in 2 cases with maxLCBI4mm <500 as
well. NIRS, also, is unable to provide detailed infor-
mation regarding luminal morphology, dimensions,
and plaque composition.
OCT imaging with higher spatial resolution (10 to
20 mm) is able to provide a comprehensive assess-
ment of plaque characteristics such as the presence
of macrophages, microchannels, microcalciﬁcations,
and the presence of the thin ﬁbrous cap. However,
it is difﬁcult to visualize the external elastic mem-
brane contour because of the lower penetration
depth (1 to 2 mm) compared with IVUS (4 to 8 mm).
The OCT studies to predict periprocedural MI
have found the cap thickness and lipid arc to be
the predictors of periprocedural MI (13,14,29). It
is conceivable that all modalities have distinct
strengths, and we compared the relative merits of
these imaging techniques in predicting periproce-
dural injury.
In the present study, the ﬁbrous cap thickness by
OCT (OR: 0.90, chi-squared: 5.55, p ¼ 0.02) showed
the highest probability to predict periprocedural MI.
Because all the target lesions are signiﬁcantly ste-
notic, it is conceivable that the thin ﬁbrous cap
indirectly indicates the presence of large necrotic or
lipid core and the independent demonstration of
lipid predominance may not be necessary. In the
recursive partition analysis of 295 autopsy specimens
from the victims of acute myocardial infarction and
sudden death, we similarly observed that the ﬁbrous
cap thickness was the most important determinant
of the unstable plaques followed by cross-section
vascular area stenosis (35). However, once the ﬁ-
brous cap thickness was excluded from the analysis
for plaque vulnerability in the autopsy specimens,
the magnitude of the necrotic core and the extent
of inﬂammation emerged as the important de-
terminants. Similar to the autopsy study, on ex-
clusion of ﬁbrous cap thickness (and other OCT
parameters) from analyses in the present study, the
plaque burden at the minimal lumen area (as
assessed by IVUS) (OR: 1.13, chi-squared: 4.04,
p ¼ 0.045) and the maximum lipid-core burden index
over the 4 mm of plaque (as assessed by NIRS) (OR:
1.003, chi-squared: 4.33, p ¼ 0.037) best explained
the periprocedural troponin leak. It is reasonable,
then, to deduce that OCT may offer the best imaging
modality for predicting periprocedural MI. If the OCT
is not available, a combination of IVUS and NIRS may
be the subsequent option. Due to the small number of
PERSPECTIVES
WHAT IS KNOWN? Myocardial damage after PCI
deﬁned as cardiac troponin elevation has been re-
ported as a procedural complication. Although
numerous studies have previously evaluated the
importance of individual imaging ﬁndings by OCT,
IVUS, or NIRS for the evaluation of periprocedural MI,
it is unclear which of the imaging tools would best
allow prediction of this complication.
WHAT IS NEW? Our head-to-head comparison of all 3
imaging modalities demonstrated that OCT-veriﬁed
TCFA was the only independent predictor for periproce-
duralMI. Plaqueburdenby IVUSor lipid corebyNIRSbest
determined the likelihood of the periprocedural event in
the absence of information about ﬁbrous cap thickness.
WHAT IS NEXT? Small number of events in the
study did not allow development of procedural algo-
rithms or determination of receiver-operating char-
acteristic curves or cutoff values of ﬁbrous cap
thickness for the likelihood of periprocedural MI.
In addition, further clinical trials are required to
determine newer antiplatelet therapy use if TCFA
is identiﬁed.
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944patients and few events, these ﬁndings should be
considered hypothesis generating rather than a
deﬁnitive result and warrant substantiation in larger
cohorts. It is important to note that regardless of
the imaging modality, the incidence of periproce-
dural complications was low. This is not surprising
and conﬁrms similar observations from the COLOR
registry (17) and CANARY (Coronary Assessment
by Near-Infrared of Atherosclerotic Rupture-Prone
Yellow) trial (36).
After post-PCI cardiac enzyme elevation has been
reported to be associated with diffuse atherosclerosis
(37) and increased adverse short- and intermediate-
term outcomes (4–10), the results from the current
study do not favor any change in stent placement
strategy. Documentation of NIRS-veriﬁed large ne-
crotic core alone as the predictor of periprocedural
myocardial injury, however, has not justiﬁed em-
ploying distal protection device in patients undergo-
ing PCI for stable disease (36). Regardless, the results
from our analysis suggest that if high-risk plaques
(i.e., those with thin ﬁbrous caps) are demonstrated
during imaging, the use of more potent antiplatelet
therapy (i.e., prasugrel, ticagrelor, glycoprotein
IIb/IIIa inhibitors) and maximal dose of statin (as
suggested by ARMYDA [Atorvastatin for Reduction
of Myocardial Damage During Angioplasty] (38))
could be considered in order to prevent periproce-
dural MI.
STUDY LIMITATIONS. The small number of events
does not allow development of procedural algorithms
or determination of receiver-operating characteristic
curves or cutoff values of ﬁbrous cap thickness for the
likelihood of periprocedural MI. Furthermore, the
relationship between cTnI $3 ULN or >5 and
clinical outcomes is unknown at this time. In addi-
tion, the present study did not include patients with
ST-segment elevation MI or with non–ST-segment
elevation acute coronary syndromes and elevated
baseline creatine kinase-myocardial band levels;
thus, our results cannot be directly extrapolated to
those higher-risk populations. We did not employ
IVUS–virtual histology in evaluation of periproce-
dural myocardial injury, which could have provided
similar/superior results and this constitutes a limita-
tion of the current study.CONCLUSIONS
Periprocedural MI, deﬁned as cTnI $3 or 5ULN, is a
small but distinct complication of PCI with signiﬁcant
consequences. OCT-based ﬁbrous cap thickness is
the most important predictor of this complication.
Plaque burden or lipid core becomes a determinant
only if the information of the ﬁbrous cap thickness
is excluded from the analysis. If high-risk plaques
are demonstrated during imaging, more potent anti-
platelet therapy (i.e., prasugrel, ticagrelor, glyco-
protein IIb/IIIa inhibitors) might be of value in
preventing periprocedural MI.
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